In today’s briefing:
- China Healthcare Weekly (Apr.6) – Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm
- STAR50 Index Rebalance Preview: APT Medical Moving Higher
China Healthcare Weekly (Apr.6) – Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm
- The biggest changes in 2023 medical insurance catalog are the lifting of payment restrictions on TCM injections, which would drive rapid sales growth in the hospital market this year.
- GLP-1s are not flawless, and patients will lose not only fat but also muscle during weight-loss process. Then, another noteworthy opportunity has emerged – reduce fat and increase muscle.
- In 2024, Sino Biopharm is expected to achieve single-digit revenue growth. Deficiencies in corporate governance are one reason why the market is reluctant to offer Sino Biopharm high valuation.
STAR50 Index Rebalance Preview: APT Medical Moving Higher
- The review period for the June rebalance ends 30 April. We expect the changes to be announced 31 May with the implementation taking place after the close on 14 June.
- We expect the index committee to continue using a 6-month minimum listing history resulting in three changes to the index.
- With a big jump in tracking AUM over the last few months, passives will need to trade a lot of stock on implementation date.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
